Nicole L Nollen1, Lisa Sanderson Cox2, Qing Yu3, Edward F Ellerbeck4, Taneisha S Scheuermann5, Neal L Benowitz6, Rachel F Tyndale7, Matthew S Mayo8, Jasjit S Ahluwalia9. 1. Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, Kansas, United States. Electronic address: nnollen@kumc.edu. 2. Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, Kansas, United States. Electronic address: lcox@kumc.edu. 3. Department of Biostatistics, University of Kansas School of Medicine, Kansas City, Kansas, United States. Electronic address: qyu@kumc.edu. 4. Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, Kansas, United States. Electronic address: eellerbe@kumc.edu. 5. Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, Kansas, United States. Electronic address: tscheuermann@kumc.edu. 6. Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco, San Francisco, California, United States; Department of Medicine, University of California, San Francisco, San Francisco, California, United States; Department of Bioengineering, University of California, San Francisco, San Francisco, California, United States; Department of Therapeutic Sciences, University of California, San Francisco, San Francisco, California, United States. Electronic address: neal.benowitz@ucsf.edu. 7. Center for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada. Electronic address: r.tyndale@utoronto.ca. 8. Department of Biostatistics, University of Kansas School of Medicine, Kansas City, Kansas, United States. Electronic address: mmayo@kumc.edu. 9. Department of Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey, United States. Electronic address: j.ahluwalia@rutgers.edu.
Abstract
BACKGROUND: African-Americans smoke fewer cigarettes per day than Whites but experience greater smoking attributable morbidity and mortality. African-American-White differences may also exist in cessation but rigorously designed studies have not been conducted to empirically answer this question. METHODS/ DESIGN: Quit2Live is, to our knowledge, the first head-to-head trial designed with the primary aim of examining African-American-White disparities in quitting smoking. Secondary aims are to identify mechanisms that mediate and/or moderate the relationship between race and quitting. The study is ongoing. Study aims are accomplished through a 5-year prospective cohort intervention study designed to recruit equal numbers of African-Americans (n=224) and Whites (n=224) stratified on age (<40, ≥40) and gender, key factors known to impact cessation, and all within a restricted income range (≤400% federal poverty level). All participants will receive 12 weeks of varenicline in combination with smoking cessation counseling. The primary outcome is cotinine-verified 7-day point prevalence abstinence from smoking at week 26. Secondary outcomes are cotinine-verified 7-day point prevalence abstinence from smoking at weeks 4 and 12. DISCUSSION: Findings from Quit2Live will not only address if African-American-White disparities in quitting smoking exist but, more importantly, will examine mechanisms underlying the difference. Attention to proximal, modifiable mechanisms (e.g., adherence, response to treatment, depression, stress) maximizes Quit2Live's potential to inform practice. Findings will provide an empirically-derived approach that will guide researchers and clinicians in identifying specific factors to address to improve cessation outcomes and reduce tobacco-related morbidity and mortality in African-American and White smokers. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT01836276.
BACKGROUND: African-Americans smoke fewer cigarettes per day than Whites but experience greater smoking attributable morbidity and mortality. African-American-White differences may also exist in cessation but rigorously designed studies have not been conducted to empirically answer this question. METHODS/ DESIGN: Quit2Live is, to our knowledge, the first head-to-head trial designed with the primary aim of examining African-American-White disparities in quitting smoking. Secondary aims are to identify mechanisms that mediate and/or moderate the relationship between race and quitting. The study is ongoing. Study aims are accomplished through a 5-year prospective cohort intervention study designed to recruit equal numbers of African-Americans (n=224) and Whites (n=224) stratified on age (<40, ≥40) and gender, key factors known to impact cessation, and all within a restricted income range (≤400% federal poverty level). All participants will receive 12 weeks of varenicline in combination with smoking cessation counseling. The primary outcome is cotinine-verified 7-day point prevalence abstinence from smoking at week 26. Secondary outcomes are cotinine-verified 7-day point prevalence abstinence from smoking at weeks 4 and 12. DISCUSSION: Findings from Quit2Live will not only address if African-American-White disparities in quitting smoking exist but, more importantly, will examine mechanisms underlying the difference. Attention to proximal, modifiable mechanisms (e.g., adherence, response to treatment, depression, stress) maximizes Quit2Live's potential to inform practice. Findings will provide an empirically-derived approach that will guide researchers and clinicians in identifying specific factors to address to improve cessation outcomes and reduce tobacco-related morbidity and mortality in African-American and White smokers. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT01836276.
Authors: Taneisha S Scheuermann; Jarron M Saint Onge; Megha Ramaswamy; Lisa Sanderson Cox; Jasjit S Ahluwalia; Nicole L Nollen Journal: Race Soc Probl Date: 2020-01-11
Authors: Nicole L Nollen; Matthew S Mayo; Lauren Clark; Lisa Sanderson Cox; Samir S Khariwala; Kim Pulvers; Neal L Benowitz; Jasjit S Ahluwalia Journal: Drug Alcohol Depend Date: 2017-08-16 Impact factor: 4.492
Authors: Dale Dagar Maglalang; Jaqueline C Avila; Jasjit S Ahluwalia; Cara M Murphy; Adam C Alexander; Nicole L Nollen Journal: Ethn Dis Date: 2022-07-21 Impact factor: 2.006
Authors: Adam C Alexander; Nicole L Nollen; Jasjit S Ahluwalia; Emily T Hébert; Michael S Businelle; Darla E Kendzor Journal: Soc Sci Med Date: 2019-09-20 Impact factor: 4.634
Authors: Annie R Peng; Walter Swardfager; Neal L Benowitz; Jasjit S Ahluwalia; Caryn Lerman; Nicole L Nollen; Rachel F Tyndale Journal: Addiction Date: 2019-11-05 Impact factor: 6.526
Authors: Nicole L Nollen; Lisa Sanderson Cox; Matthew S Mayo; Edward F Ellerbeck; Sheshadri Madhusudhana; Jasjit S Ahluwalia Journal: Contemp Clin Trials Date: 2018-05-19 Impact factor: 2.226
Authors: Nicole L Nollen; Matthew S Mayo; Lisa Sanderson Cox; Neal L Benowitz; Rachel F Tyndale; Edward F Ellerbeck; Taneisha S Scheuermann; Jasjit S Ahluwalia Journal: J Natl Cancer Inst Date: 2019-10-01 Impact factor: 13.506
Authors: Nicole L Nollen; Matthew S Mayo; Jarron M Saint Onge; Taneisha S Scheuermann; Lisa Sanderson Cox; David Chae; Eleanor Leavens; Jasjit S Ahluwalia Journal: Exp Clin Psychopharmacol Date: 2021-08-09 Impact factor: 3.492
Authors: Catherine S Nagawa; Jeroan A Allison; Stephenie C Lemon; Kathleen M Mazor; Thomas K Houston; Rajani S Sadasivam; Jamie M Faro Journal: JMIR Mhealth Uhealth Date: 2020-04-27 Impact factor: 4.773